06:22 AM EDT, 08/07/2024 (MT Newswires) -- Organigram Holdings ( OGI ) , a licensed producer of cannabis, released the preliminary results of a clinical pharmacokinetic (PK) study conducted via the Product Development Collaboration (PDC) on its latest innovation, nanoemulsion technology.

A statement said this patent-pending technology, branded FASTTM (Fast Acting Soluble Technology), will be the first innovation to be commercialized by Organigram ( OGI ).

Wednesday's statement noted the clinical study was completed in January 2024, and the final data set has been received and reviewed. The final report is expected to be published in October 2024.

Organigram ( OGI ) said the results of the study have given early indications of technological advances, including but not limited to: Faster onset compared to traditional ingestible products from the control group; and depending on ingestible format, up to approximately 50% faster onset of the effects of cannabis was observed.

It added the results also indicated improved bioavailability of cannabinoids, up to double the cannabinoid delivery at peak compared to the control group; and early indicators of a more predictable duration of the effects of cannabis showing promising signals for the development of future offset claims, subject to additional supporting studies.

The PDC is a joint collaboration between BAT and Organigram ( OGI ) and was established to focus on developing next-generation cannabis products.

OGI rose $0.05 or 2.4% on the TSX yesterday, and 7% on the Nasdaq.